Ascendis Pharma A/S (ASND) to Release Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is set to issue its quarterly earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to analyst estimates of $94.74 million. On average, analysts expect Ascendis Pharma A/S to post $-7 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Ascendis Pharma A/S Price Performance

ASND stock opened at $127.67 on Wednesday. Ascendis Pharma A/S has a 1-year low of $86.54 and a 1-year high of $161.00. The business has a 50-day moving average price of $131.91 and a 200 day moving average price of $132.90. The company has a market capitalization of $7.74 billion, a P/E ratio of -13.71 and a beta of 0.66.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ASND shares. Wells Fargo & Company boosted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a report on Tuesday, September 17th. StockNews.com lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday. Wedbush upgraded Ascendis Pharma A/S to a “strong-buy” rating in a report on Monday, November 4th. Bank of America boosted their price target on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. Finally, Citigroup raised their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $195.92.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.